Among the radiopharmaceuticals which selectively concentrate in medullary thyroid carcinoma (MTC), radioiodinated MIBG and 99mTc(V)DMSA have been widely used. A scintigraphic method employing a radiolabeled somatostatin analog (111In-pentetreotide) has been recently developed (SMS scintigraphy). The authors report the results obtained with the three radiopharmaceuticals in a group of patients with proven MTC. In 33 patients 123/131I-MIBG imaging showed a high specificity (no false-positive results) but a low sensitivity (32%). In 22 patients 99mTc(V)DMSA revealed a better sensitivity (70%) but a lower specificity (three false positive results). Positive results were obtained in 5/9 patients studied with SMS scintigraphy. 99mTC(V)DMSA confirms its role as a first choice technique in the follow up of patients with MTC. SMS scintigraphy gives results comparable to 99mTc(V)DMSA; it has a therapeutic impact also, predicting tumor response to long-term therapy with octreotide. MIBG scintigraphy, in spite of its low sensitivity, can play a role in MTC for its therapeutic possibilities in cases with positive results.
Nuclear medicine imaging in medullary thyroid carcinoma
Corsello S;
1994-01-01
Abstract
Among the radiopharmaceuticals which selectively concentrate in medullary thyroid carcinoma (MTC), radioiodinated MIBG and 99mTc(V)DMSA have been widely used. A scintigraphic method employing a radiolabeled somatostatin analog (111In-pentetreotide) has been recently developed (SMS scintigraphy). The authors report the results obtained with the three radiopharmaceuticals in a group of patients with proven MTC. In 33 patients 123/131I-MIBG imaging showed a high specificity (no false-positive results) but a low sensitivity (32%). In 22 patients 99mTc(V)DMSA revealed a better sensitivity (70%) but a lower specificity (three false positive results). Positive results were obtained in 5/9 patients studied with SMS scintigraphy. 99mTC(V)DMSA confirms its role as a first choice technique in the follow up of patients with MTC. SMS scintigraphy gives results comparable to 99mTc(V)DMSA; it has a therapeutic impact also, predicting tumor response to long-term therapy with octreotide. MIBG scintigraphy, in spite of its low sensitivity, can play a role in MTC for its therapeutic possibilities in cases with positive results.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
